DOMAB Trademark

Trademark Overview

On Tuesday, August 10, 2021, a trademark application was filed for DOMAB with the United States Patent and Trademark Office. The USPTO has given the DOMAB trademark a serial number of 90874295. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, June 12, 2023. This trademark is owned by Boston Immune Technologies and Therapeutics, Inc.. The DOMAB trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development services in the field of antibodies
domab

General Information

Serial Number90874295
Word MarkDOMAB
Filing DateTuesday, August 10, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, June 12, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development services in the field of antibodies

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 4, 2021
Primary Code042
First Use Anywhere DateSunday, January 31, 2016
First Use In Commerce DateSunday, January 31, 2016

Trademark Owner History

Party NameBoston Immune Technologies and Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWinchester, MA 01890

Trademark Events

Event DateEvent Description
Monday, June 12, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, June 12, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, June 12, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, November 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 28, 2022NON-FINAL ACTION E-MAILED
Monday, November 28, 2022NON-FINAL ACTION WRITTEN
Tuesday, November 22, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, November 22, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 22, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, November 22, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, July 21, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 21, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 21, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, July 18, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, July 18, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 18, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 10, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 10, 2022NON-FINAL ACTION E-MAILED
Tuesday, May 10, 2022NON-FINAL ACTION WRITTEN
Tuesday, May 10, 2022ASSIGNED TO EXAMINER
Monday, October 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 13, 2021NEW APPLICATION ENTERED

Related Keywords

domab antibodies field services development research